With this cash position expected to fund operations into 2027, and supplemented by ongoing collaboration payments from Kyowa Kirin, Kura has effectively de-risked its financial outlook through potential commercialization. Revenue generation has begun with $15.3 million recognized from the Kyowa Kirin partnership in Q2 2025, representing a new positive financial dynamic compared to no revenue in the prior year period. The $66.1 million net loss reflects appropriate investment scaling as the company transitions toward commercial readiness, with R&D expenses increasing to $62.8 million (from $39.7 million) and G&A expanding to $25.2 million (from $16.7 million). The completed hiring of the U.S. sales team ahead of the November PDUFA date indicates management's confidence in approval and demonstrates proper operational execution. This strategic investment is critical as commercial preparations typically require 6-9 months lead time for successful launches in oncology.